<?xml version="1.0" encoding="UTF-8"?>
<ref id="B4">
 <label>4.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Gouglas</surname>
    <given-names>D</given-names>
   </name>, 
   <name name-style="western">
    <surname>Le</surname>
    <given-names>TT</given-names>
   </name>, 
   <name name-style="western">
    <surname>Henderson</surname>
    <given-names>K</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kaloudis</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Danielsen</surname>
    <given-names>T</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hammersland</surname>
    <given-names>NC</given-names>
   </name>, 
   <name name-style="western">
    <surname>Robinson</surname>
    <given-names>JM</given-names>
   </name>, 
   <name name-style="western">
    <surname>Heaton</surname>
    <given-names>PM</given-names>
   </name>, 
   <name name-style="western">
    <surname>Røttingen</surname>
    <given-names>J-A</given-names>
   </name>
  </person-group>
  <year>2018</year>
  <article-title>Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study</article-title>. 
  <source>Lancet Glob Health</source>
  <volume>6</volume>:
  <fpage>e1386</fpage>−
  <lpage>e1396</lpage>. doi:
  <pub-id pub-id-type="doi">10.1016/S2214-109X(18)30346-2</pub-id>.
  <pub-id pub-id-type="pmid">30342925</pub-id>
 </mixed-citation>
</ref>
